digital therapeutics
-
Digital Therapeutics: A Panacea for Care or Overvalued Health Tech?
Digital therapeutics will be one of the topics discussed at INVEST Digital Health scheduled for October 26 at Health Wildcatters headquarters in Pegasus Park in Dallas. Register today!
-
Devices & Diagnostics, BioPharma
Click Expands to Substance Use Disorder With Indivior Digital Therapeutics Pact
Digital therapeutics developer Click Therapeutics is partnering with Indivior to develop a mobile app for substance use disorder. Indivior is now Click’s third development partner, following deals with Boehringer Ingelheim and Otsuka Pharmaceutical.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
Devices & Diagnostics, BioPharma
Rigorous Data Are Key to Convince Payers, Investors in the World of Digital Therapeutics
Pear Therapeutics was once regarded as a digital therapeutics pioneer, but its spiral into bankruptcy has the industry searching for the best path forward. While some favor going direct to consumers, others say the solution is in generating more robust clinical trial data to persuade hesitant payers.
-
MedCity Influencers, Health Tech
What Pear Therapeutics’ Bankruptcy Has Left the DTX Industry to Ponder
One of the fastest-growing frontiers of healthcare is Digital Therapeutics (DTx), which utilizes clinically tested […]
-
MedCity Influencers, BioPharma
In Therapeutic Innovation, Digital Must Be Held to the Same Rigor as Biotech
The challenge of introducing a novel therapy is nothing new. It has been done again and again, but always from a foundation of compelling evidence…gathered through a rigorous scientific approach that demonstrates quality, safety, efficacy, and a favorable balance of benefits and risks.
-
Artificial Intelligence, BioPharma
Why Sofinnova is Betting on the Confluence of Digital Technology and the Life Sciences
Paris-based Sofinnova Partners announced last week that it has launched a new strategy aimed at investing in a new breed of startups that straddle the lines between data and biology.
-
AppliedVR Earns First Unique CMS Code Ever Granted to a Digital Therapeutic
CMS recently established a unique code for AppliedVR’s flagship product, marking the first time a digital therapeutic or immersive therapeutic has ever been placed in an existing benefit category. The eight-week program is a physician-prescribed solution that allows patients to manage their chronic lower back pain without opioids from the comfort of their own home.
-
Pear Therapeutics’ Cuts Are Not Enough; ‘Strategic Alternatives’ Among Next Steps
Pear Therapeutics isn’t meeting the commercialization goals for its prescription digital therapeutics, so it’s now seeking strategic alternatives for the business. Prospective buyers can pick up Pear’s FDA-cleared products for substance use disorder, opioid use disorder, and insomnia.
-
MedCity Influencers, Devices & Diagnostics, BioPharma, Health Tech
The Drive to Adopt Digital Therapeutics: Where do we Stand?
As regulatory processes and reimbursements are refined, there needs to be a continued focus on how to maximize the benefits for patients and ensure DTx can play a role in improving outcomes. The key to this is integration into the clinical workflow.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
MedCity Influencers, Health Tech
The Challenges, Potential, and Future of Digital Therapeutics in Healthcare
Earlier this year, CMS implemented a new Level II Healthcare Common Procedure Coding System (HCPCS) code for “prescription digital behavioral therapy,” which makes it easier for commercial and Medicaid plans to cover these therapies. Additionally
-
RTM Reimbursement Represents a New Age for Digital Therapeutics
Ultimately, it is anticipated that CMS will further expand the use of reimbursable RTM beyond respiratory and MSK care and incorporate patient-reported information as a requirement for reimbursement of certain remote services.
-
How pharma companies can leverage asynchronous telemedicine
Through apps, pharmaceutical companies can actually influence patient adherence and mindset after that patient has been prescribed that company’s medication by their physician.
-
MedCity Influencers, Health Tech
Why better heart health worldwide is now within reach
By placing the power to detect atrial fibrillation into the hands of 6 billion global smartphone users, validation of further physiological parameters will be expedited and the subsequent adoption of this technology into DTx will enable the low-cost tools required to remove barriers to care and improve heart health across the globe.
-
Overcoming obstacles in digital medicine
A panel discussion on the future of digital medicine highlighted some of the collaborations taking place between pharma companies and digital health, as well as some of the challenges facing the push towards mainstream implementation.
-
MedCity Influencers, BioPharma
A call to action for pharma manufacturers: Rise to the challenge of global medicine access with the help of digitalization
Operational efficiency and visibility brought on by digital transformation can help improve how pharmaceutical manufacturers do their critical part in improving equitable access and availability of medicine around the world.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
